PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present in a virtual format at the following conferences:
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities, its 2020 Annual Meeting of Stockholders, has been changed to a virtual meeting to be held on Wednesday, June 10, 2020 at 2:00 p.m. Eastern Time. Stockholders will be able to participate in this year's Annual Meeting only via the virtual meeting.
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -116.98% and 8.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd at 1:00 p.m. ET.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in the series will discuss its Bio-e platform on Friday, June 5 at 10:00 a.m. ET.
Q4 2019 PTC Therapeutics Inc Earnings Call
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. The transaction was approved by the Boards of both companies.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Marcio Souza, Chief Operating Officer, has resigned and will be leaving the company by April 25th, 2020.
Intercept Pharmaceuticals hoping for approval on medication to compete in large and fast-growing market for NASH treatments Continue reading...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive results from part 2 of the pivotal FIREFISH study evaluating risdiplam in infants with type 1 spinal muscular atrophy (SMA). The global study met its primary endpoint of infants sitting without support for five seconds by month 12, as assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III). Type 1 SMA babies do not achieve this milestone without therapy. Substantial results were demonstrated across multiple secondary and exploratory endpoints, as infants in the study achieved milestones not seen in natural history. In addition to being able to sit without support, infants were able to maintain upright head control, roll to the side, and stand without support after 12 months of treatment. At 12 months, 95% infants maintained the ability to swallow and 89% were able to feed orally. No new safety signals were identified in part 2 of the study. These data will be reviewed during a conference call today at 11:30 am ET by our development partner, Roche.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
PTC Therapeutics, Inc. (NASDAQ:PTCT) shares fell 4.6% to US$51.86 in the week since its latest yearly results...
Q1 2020 PTC Therapeutics Inc Earnings Call
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Matthew Klein, M.D., to Chief Development Officer and Eric Pauwels to Chief Business Officer. Dr. Klein will be responsible for the development of our clinical stage programs. As the Chief Business Officer, Mr. Pauwels will be responsible for our customer facing activities with health care providers, patients and payers ensuring that our therapies are available and accessible to rare disease patients and their families worldwide.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 11, 2020 it approved non-statutory stock options to purchase an aggregate of 50,025 shares of its common stock and 4,470 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to seven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of risdiplam to August 24, 2020. Roche recently submitted additional data including comprehensive data from SUNFISH part 2 to help provide access to risdiplam for a broad range of people living with spinal muscular atrophy (SMA), triggering this extension. The FDA has informed Roche that the review team is working expeditiously to complete their review of the application as quickly as possible. The FDA has also indicated to Roche that no substantive review issues have been identified to date.
A growing number of Covid-19 cases could frustrate biotech companies' efforts to enroll patients in clinical studies, an analyst said Tuesday. This could impact Intercept and Gilead.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2020 financial results and provide an update on the company's business and outlook on Thursday, April 30, 2020 at 4:30 p.m. (ET) after the closing of the market.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.